Research programme: interleukin inhibitors - Rigel

Drug Profile

Research programme: interleukin inhibitors - Rigel

Alternative Names: AZD 0449; R 256

Latest Information Update: 17 Nov 2014

Price : $50

At a glance

  • Originator Rigel Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors; Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 30 Sep 2014 AstraZeneca initiates an IND-enabling toxicology study of R 256 in Asthma
  • 19 Jun 2012 R 256 licensed to AstraZeneca worldwide for the treatment of Asthma
  • 01 Jan 2012 Preclinical trials in Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top